Shoma Barat

Shoma Barat is a researcher at the University of New South Wales specializing in cancer surgery with a focus on peritoneal surface malignancies. Her work centers on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancers, with numerous publications examining survival outcomes, treatment protocols, and prognostic indicators.

Ms. Barat holds a BSc in Microbiology, a Graduate Certificate in Medical Technology, a Graduate Diploma in Analytical Chemistry, and a Master's degree in Health Information Management from the University of Sydney. Her educational background combines microbiology, medical technology, and health informatics, providing a multidisciplinary foundation for her cancer research.

Her research interests span several critical areas in surgical oncology, with particular emphasis on peritoneal metastases management. She investigates differences between appendiceal and colon cancer treatments, outcomes for patients with high-volume peritoneal disease, and the prognostic value of biomarkers like the CEA/PCI ratio. Her work examines how factors such as age, PCI scores, and cancer subtypes impact patient survival and quality of life.

Analysis of Ms. Barat's publication record reveals a consistent focus on clinically relevant questions in peritoneal surface malignancy treatment. Her research demonstrates how cytoreductive surgery combined with HIPEC can be optimized for different cancer types and patient populations. A notable trend is her investigation of prognostic tools that help clinicians determine which patients will benefit most from aggressive surgical interventions.

Ms. Barat works closely with Professor David Morris and an international research team specializing in peritoneal surface malignancies. Her collaborative network includes researchers from multiple continents, reflecting the global nature of this specialized cancer treatment approach. Her work contributes significantly to evidence-based protocols for managing complex peritoneal cancers.